October 08, 2020
Subpotency concerns have prompted Arbor Pharmaceuticals Inc. to recall a single lot of Nymalize (nimodipine) oral solution, according to the October 7, 2020, US Food and Drug Administration (FDA) Enforcement Report.
The recall affects 1846 cartons of Nymalize, 60 mg/20 mL, each containing 12 unit-dose cups and 12 oral syringes (NDC 24338-200-12), from lot 356884 (Exp. 11/30/21). The cartons were distributed throughout the United States.
Arbor Pharmaceuticals voluntarily initiated the recall September 16, 2020. On September 28, 2020, the FDA designated the recall Class III, suggesting use of the recalled product is not likely to cause harm.
Nymalize is a prescription drug used to improve outcomes in adults with subarachnoid hemorrhage.